CJC-1295 without DAC vs DSIP

CJC-1295 without DAC (Mod GRF 1-29)

Tetra-substituted GHRH (1-29) with no Drug Affinity Complex, so it clears in roughly 30 minutes and produces a single discrete GH pulse. That short half-life is the whole point: it is dosed once to three times daily, typically around 100 mcg (roughly 1-2 mcg/kg, a saturating pulse dose) on an empty stomach, and is paired with a ghrelin agonist such as ipamorelin. It is NOT an approved medicine; the closest approved comparators are sermorelin and tesamorelin. Consumer supply is research-chemical grade and dosing convention comes from practice, not from a label.

DSIP (Delta Sleep-Inducing Peptide)

DSIP is a nine-amino-acid peptide isolated in the 1970s by Monnier, Schoenenberger and colleagues from the cerebral venous blood of rabbits in electrically induced delta-wave sleep, which is where the name comes from. It is not approved anywhere and has no modern development program. The human evidence is old, small and sparse, and it does not show what the name implies. The controlled work is a handful of studies from roughly 1977 to the early 1990s, mostly with a few dozen subjects at most, and the effects on sleep architecture were modest and inconsistent between groups. Some of the more repeatable findings were not in insomnia at all but in chronic pain and in opiate and alcohol withdrawal. DSIP is not a sedative and does not behave like one: it does not reliably knock anyone out, and whether an injected dose crosses the blood-brain barrier intact in meaningful quantity is still disputed. Treat any claim of a strong hypnotic effect as unsupported. On dosing, the classic human studies gave roughly 25 nmol/kg intravenously - about 1.5 mg for a 70 kg adult - which is both a different route and a much larger amount than anyone injects subcutaneously today. That figure has deliberately NOT been used to set the ceiling here. The 100-500 mcg subcutaneous range with a typical dose around 200 mcg reflects contemporary community practice, taken shortly before bed; there is no trial behind that range, and no dose-response curve exists for this route. Plasma half-life is reported in minutes, so no hourly figure is listed. The four-week cycle length is convention rather than evidence - no study has run long enough to establish a course length, and nothing is known about tolerance or long-term use.